This study assessed sonrotoclax plus zanubrutinib in untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients. Among 137 patients, the investigational combination was generally well tolerated, with no treatment-related deaths reported. The most common any-grade treatment-emergent AEs (TEAEs) were neutropenia, COVID-19, contusion, and diarrhea. No clinical or laboratory tumor lysis syndrome (TLS) occurred, and only 9 patients discontinued combination treatment due to TEAEs. All patients responded to therapy, and nearly all achieved deep remission (undetectable disease in the blood). These deep responses occurred early and were maintained over time, including in patients with high-risk genetic features. The results support further research into this combination as a frontline therapy for CLL/SLL.

The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.